Cat. #151100
Anti-PCTAIRE [G6.1]
Cat. #: 151100
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: PCTAIRE
Class: Monoclonal
Application: IHC ; IP ; WB
Reactivity: Mammalian ; Xenopus laevis
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Julian Gannon
Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-PCTAIRE [G6.1]
- Alternate name: Cyclin-Dependent Kinase 16; Serine/Threonine-Protein Kinase PCTAIRE-1; Cell Division Protein Kinase 16; PCTAIRE-Motif Protein Kinase 1; PCTAIRE1; PCTK1; Testis Secretory Sperm-Binding Protein Li 224n; Serine/Threonine-Protein Kinase; PCTGAIRE
- Research fields: Cell signaling and signal transduction
- Clone: G6.1
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 200 kDa
- Strain: Balb/c
- Reactivity: Mammalian ; Xenopus laevis
- Host: Mouse
- Application: IHC ; IP ; WB
- Description: PCTAIRE is a member of the CDK family of protein kinases which is related to CDK1.
- Immunogen: PCTAIRE Peptide (DRMKKIKRQLSMTLRGGRC from amino terminus) + Freunds Adjuvant .
- Isotype: IgG2b
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: PCTAIRE
- Molecular weight: 200 kDa
- Target background: PCTAIRE is a member of the CDK family of protein kinases which is related to CDK1.
Applications
- Application: IHC ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Graeser et al. 2002. J Cell Sci. 115(Pt 17):3479-90. PMID: 12154078.
- Regulation of the CDK-related protein kinase PCTAIRE-1 and its possible role in neurite outgrowth in Neuro-2A cells.
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)
![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)
